Camp4 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-51.77	-51.79	-49.29	-44.19
Depreciation & Amortization	1.68	1.7	1.68	0.88
Stock-Based Compensation	4.04	4.03	2.91	1.38
Other Operating Activities	1.99	1.83	1.82	1.69
Change in Accounts Payable	-0.64	0.17	-1.12	1.33
Change in Unearned Revenue	-	0.39	-	-
Change in Other Net Operating Assets	-4	-1.88	-0.15	0.37
Operating Cash Flow	-48.71	-45.56	-44.16	-38.54
Capital Expenditures	-0.71	-0.44	-0.68	-4.03
Investing Cash Flow	-0.71	-0.44	-0.68	-4.03
Long-Term Debt Issued	-	-	0.71	-
Long-Term Debt Repaid	-	-0.82	-0.59	-0.09
Net Debt Issued (Repaid)	-0.77	-0.82	0.12	-0.09
Issuance of Common Stock	76.46	76.47	0.19	0.06
Other Financing Activities	-3.98	-3.98	-	-
Financing Cash Flow	71.71	71.66	0.3	100.16
Net Cash Flow	22.3	25.66	-44.53	57.59
Free Cash Flow	-49.41	-46	-44.83	-42.57
Free Cash Flow Margin	-3272.19%	-7055.67%	-12809.43%	-
Free Cash Flow Per Share	-5.14	-9.81	-113.51	-136.31
Levered Free Cash Flow	-	-26.54	-30.18	-
Unlevered Free Cash Flow	-	-26.52	-30.16	-
Change in Net Working Capital	-	-1.37	1.65	-

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q